Aman Chauhan: Launching New Clinical Trial for High-Grade Neuroendocrine Carcinoma
Aman Chauhan, Leader of Neuroendocrine Cancer Program at Sylvester Comprehensive Cancer Center, shared Sylvester Comprehensive Cancer Center‘s post on X, adding:
“High grade neuroendocrine carcinoma are rare and a critical unmet need.
HGNEC afflicts young and old across various organ systems. I crossed my path with Austin during my impressionable early career phase and his cancer journey inspired me to devote a substantial part of my research into HGNECs.
Several years later, we finally have a ray of hope. We launched our investigator initiated SVV-001 plus Ipi-Nivo study this week. We are also partnering with key industry leaders and patient advocates in helping develop new drugs for NEC:
Be it DLL-3 targeting T cell engagers or Radiopharmaceuticals, the field is definitely moving in the right direction.”
Quoting Sylvester Comprehensive Cancer Center post on X:
“Sylvester is now enrolling patients in a new clinical trial targeting high-grade neuroendocrine tumors — a rare, aggressive disease with limited treatment options and few medical advances.
Aman Chauhan and his team previously tested the strategy in preclinical models, where it led to tumor shrinkage and lasting responses.”
Clinical Trial Opens for Patients with High-Grade Neuroendocrine Cancer
More posts Aman Chauhan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023